Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses Academic Article uri icon

Overview

MeSH Major

  • Immunoglobulin Idiotypes
  • Immunotherapy
  • Lymphoma, Non-Hodgkin

abstract

  • This trial demonstrates that Id/KLH alone can induce tumor regression and durable objective responses. Further study of Id/KLH is recommended in other settings where efficacy may be further enhanced as in first-line therapy or after cytoreductive therapy.

publication date

  • July 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.04.4289

PubMed ID

  • 16754937

Additional Document Info

start page

  • 3107

end page

  • 12

volume

  • 24

number

  • 19